Encouragingly, the potential clinical benefit of IL-33 blockade has been indicated by phase 2 clinical studies in patients with moderate-to-severe asthma and in former smokers with chronic obstructive pulmonary disease.47 The gene discussed is IL33; the disease is chronic obstructive pulmonary disease.